Paul T Quinlan sold $936k of ORKA
General Counsel at Oruka Therapeutics, Inc.. 10,000 shares at an average of $93.64, traded Sep 21, 2026, filed Sep 21, 2026.
Score components
- +15RoleOfficer
- +24Trade size$936k at market
- +10Share of holdings soldSold 25% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000907654-26-000100, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | MOption exercise Common Stock10b5-1 | +10,000 | $7.80 | $78k | 39,995 | 21 d ago |
| Sep 21, 2026 | SOpen-market sale Common Stock10b5-1 | -2,900 | $92.37 | $268k | 37,095 | 21 d ago |
| Sep 21, 2026 | SOpen-market sale Common Stock10b5-1 | -3,832 | $93.32 | $358k | 33,263 | 21 d ago |
| Sep 21, 2026 | SOpen-market sale Common Stock10b5-1 | -601 | $94.44 | $57k | 32,662 | 21 d ago |
| Sep 21, 2026 | SOpen-market sale Common Stock10b5-1 | -2,667 | $95.31 | $254k | 29,995 | 21 d ago |
| Sep 21, 2026 | MOption exercise Employee Warrant (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 79,996 | 21 d ago |
Related signals
Other insiders at Oruka Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $2.1M 25,000 shares | -3% | |
| 17Weak | Oruka Therapeutics, Inc. | Arjun Agarwal Senior Vice President, Finance | $51k 533 shares | -4% | |
| 29Weak | Oruka Therapeutics, Inc. | Arjun Agarwal Senior Vice President, Finance | $926k 10,019 shares | -40% | |
| 21Weak | Oruka Therapeutics, Inc. | Joana Goncalves Chief Medical Officer | $734k 7,947 shares | -20% | |
| 53Moderate | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $235k 2,452 shares | -0% | |
| 44Moderate | Oruka Therapeutics, Inc. | Laura Lee Sandler Chief Operating Officer | $87k 906 shares | -0% | |
| 40Moderate | Oruka Therapeutics, Inc. | Paul T Quinlan General Counsel | $99k 1,039 shares | -3% | |
| 30Weak | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $6.9M 75,000 shares | -7% | |
| 17Weak | Oruka Therapeutics, Inc. | Laura Lee Sandler Chief Operating Officer | $459k 5,000 shares | -2% | |
| 32Weak | ORKAbuy Oruka Therapeutics, Inc. | Venrock Healthcare Capital Partners III, L.P. owner | $1.4M 122,882 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.